Clinical trials: Crohn Disease
Arthritis, Rheumatoid, Spondylitis, Ankylosing
One-year Persistence to Treatment of Participants Receiving Flixabi or Imraldi: a French Cohort Study
A study to describe the one-year persistence in participants treated by Flixabi (infliximab) or Imraldi (Adalimumab) as prescribed by the physician for each of the 5 following indications: Rheumatoid Arthritis (RA), Ankylosing…
- Conditions
- Arthritis, Rheumatoid, Spondylitis, Ankylosing, Arthritis, Psoriatic, Crohn's Disease
- Trial name
- PERFUSE (NCT03662919)
- Testing
- Infliximab, Adalimumab
- Where
- 60 sites in France
- Volunteers
- 2,274 people
- Sponsor
- Biogen
Crohn's Disease
A Study of Adalimumab for the Maintenance of Clinical Remission in Japanese Subjects With Crohn's Disease
To demonstrate the efficacy and safety of adalimumab for the maintenance of clinical remission in Japanese subjects with Crohn's disease.
- Trial name
- NCT00445432
- Testing
- adalimumab
- Where
- 29 sites in Japan
- Volunteers
- 82 people
- Sponsor
- Abbott
Rheumatoid Arthritis, Psoriatic Arthritis
Surveillance of Humira Injection in Korean Patients
Patients who take Humira as prescribed by physicians as per Korean label will be enrolled and observed in normal medical practice setting for not less than 3 months following first dose of Humira.
- Conditions
- Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease
- Trial name
- NCT01083121
- Where
- 77 sites in South Korea
- Volunteers
- 1,779 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Crohn Disease
A Study to Test Whether BI 706321 Combined With Ustekinumab Helps People With Crohn's Disease
This study is open to adults, aged 18-75 years, with moderate to severe Crohn's disease. The purpose of this study is to find out whether BI 706321 combined with ustekinumab helps people with Crohn's disease.
- Trial name
- NCT04978493
- Testing
- BI 706321, Ustekinumab
- Where
- 49 sites in United States, Belgium and 9 more
- Volunteers
- 49 people
- Sponsor
- Boehringer Ingelheim
Crohn's Disease
Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease
The purpose of this study is to evaluate endoscopic remission at Week 26 as assessed by ileocolonoscopy.
- Trial name
- NCT02425111
- Testing
- Vedolizumab
- Where
- 79 sites in United States, Belgium and 6 more
- Volunteers
- 101 people
- Sponsor
- Takeda
Crohn Disease, Inflammatory Bowel Disease
Health-Related Quality of Life in Crohn's Disease Participants With Complex Perianal Fistula Before and After Treatment
The purpose of this study is to assess the impact of treatment (medical and/or surgical) on Health-related Quality of Life (HRQoL) in participants with Crohn's Disease (CD) and Complex Perianal Fistula (CPF), by the Quality of…
- Conditions
- Crohn Disease, Inflammatory Bowel Disease, Gastrointestinal Diseases, Intestinal Diseases
- Trial name
- CALYPSO (NCT04102163)
- Where
- 20 sites in Spain
- Volunteers
- 19 people
- Sponsor
- Takeda
Crohn's Disease
A Dose-finding and Confirmatory Trial of OPC-6535 in Patients With Active Crohn's Disease
The purpose of this study is to verify the safety and efficacy of OPC-6535 and determine the optimal dose by once-daily oral administration of OPC-6535 at 25 or 50 mg or placebo for 8 weeks in combination with base treatment…
- Trial name
- NCT00989573
- Testing
- OPC-6535
- Where
- 11 sites in Japan, South Korea
- Volunteers
- 191 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Crohn Disease
A Study of Infliximab in the Treatment of Chinese Children With Crohn's Disease
The main purpose of this study is to record the use of Infliximab (IFX) in the treatment of Chinese children with Crohn's disease (CD) in routine clinical practice and to summarize the clinical efficacy and safety of IFX in the…
- Trial name
- NCT04312659
- Testing
- Infliximab
- Where
- 5 sites in China
- Volunteers
- 38 people
- Sponsor
- Johnson & Johnson (China) Investment Ltd.
Crohn's Disease
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical…
- Trial name
- MACARONI-23 (NCT05923073)
- Testing
- Guselkumab
- Where
- 85 sites in United States, Australia and 15 more
- Volunteers
- 120 people
- Sponsor
- Janssen Research & Development, LLC
Inflammatory Bowel Diseases, Colitis, Ulcerative
Initial Experience With a Novel Single-Balloon Enteroscopy System in Children With IBD
To evaluate the safety and efficacy of the NaviAid™ AB in children with known or suspected IBD.
- Conditions
- Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease
- Trial name
- NCT02629211
- Testing
- NaviAid™ AB
- Where
- Israel
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Smart Medical Systems Ltd.
Crohn Disease
Positron Emission Tomography Study of Changes in [11C]AZ14132516 Uptake Following Administration of AZD7798 to Patients With Crohn's Disease.
The purpose of this study is to measure the changes in intestinal uptake of radioligand [11C]AZ14132516 following multiple doses of AZD7798 in participants with Crohn's disease.
- Trial name
- NCT06432764
- Testing
- AZD7798, [11C]AZ14132516
- Where
- Sweden
- Volunteers
- 9 people
- Sponsor
- AstraZeneca
Crohn's Disease
Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease
To compare the efficacy, safety and pharmacokinetics of ABT-874 to placebo in subjects who have moderately to severely active Crohn's Disease.
- Trial name
- NCT00562887
- Testing
- ABT-874
- Where
- 61 sites in United States, Australia and 5 more
- Volunteers
- 246 people
- Sponsor
- Abbott
Crohn´s Disease
A Study With Pentasa in Patients With Active Crohn's Disease
The purpose of this trial is to demonstrate that Pentasa administered as a 2 g morning dose and a 4 g evening dose is efficacious in active mild to moderate CD.
- Trial name
- PEACE (NCT00862121)
- Testing
- Pentasa
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 20 people
- Sponsor
- Ferring Pharmaceuticals
Crohn's Disease
Blood and Stool Molecular Biomarkers Longitudinal Detection Study in Crohn's Disease (CD) Patients
To evaluate the relationship between noninvasive biomarkers (patient serological markers and metagenomic analysis of stool) and disease status as determined by colonoscopy and by clinical symptoms in patients with Crohn's…
- Trial name
- NCT03566407
- Testing
- Colonoscopy
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- Prometheus Laboratories
Crohn's Disease
The Safety And Efficacy Of Maintenance Therapy With CP-690,550
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease who completed the double-blind induction treatment in Study A3921083 and achieved clinical response-100 and/or…
- Trial name
- NCT01393899
- Testing
- CP-690,550
- Where
- 91 sites in United States, Australia and 15 more
- Volunteers
- 180 people
- Sponsor
- Pfizer
Crohn's Disease
Study Evaluating ERB-041 in Active Crohn's Disease
Evaluate the response of inflammatory serum markers to oral ERB-041 in subjects with inflammation associated with active Crohn's disease.
- Trial name
- NCT00245947
- Testing
- ERB-041
- Volunteers
- 22 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Crohn's Disease
A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one of the dose levels to be tested will be more effective than placebo…
- Trial name
- NCT00615199
- Testing
- CP-690,550
- Where
- 72 sites in United States, Belgium and 10 more
- Volunteers
- 139 people
- Sponsor
- Pfizer
Crohn's Disease
Visilizumab for Treatment of Perianal Fistulas in Crohn's Disease
The purpose of the study is to evaluate an intravenous (by injection) investigational medication to treat Crohn's disease in patients with at least one perianal fistula.
- Trial name
- NCT00267709
- Testing
- Visilizumab
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Facet Biotech
Crohn's Disease
A Study To Investigate Safety And Efficacy Of CP-690,550 For Induction Therapy In Subjects With Moderate To Severe Crohn's Disease
This study investigates safety and efficacy of CP-690,550 in adult patients with moderate to severe Crohn's disease. The study hypothesis is that at least one dose of the tested drug is more effective than placebo (inactive drug).
- Trial name
- NCT01393626
- Testing
- CP-690,550
- Where
- 140 sites in United States, Australia and 16 more
- Volunteers
- 280 people
- Sponsor
- Pfizer
Crohn's Disease
Program Extension of Real Life Dosing of Remicade in Austria for Crohn's Disease (Study P04052)(COMPLETED)
The current observational program was determined to collect data on the real life dosing regimen of Remicade in patients with Crohn's disease (CD) in the hospital and non-hospital setting.
- Trial name
- NCT00724958
- Testing
- Infliximab
- Volunteers
- 348 people
- Sponsor
- Merck Sharp & Dohme LLC